国药控股披露子公司国药一致2026年前三季度业绩快报：前三季营收550.66亿元微降0.11%、净利9.52亿元降0.48%，Q3单季净利增长18.91%

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no
responsibility for the contents of this announcement, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in
reliance upon the whole or any part of the contents of this announcement.




ANNOUNCEMENT
PRELIMINARY FINANCIAL DATA OF SINOPHARM ACCORD
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2026
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of
Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and
Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the
“Company”) dated 20 October 2026 (the “Announcement”) in relation to the preliminary
financial data for the nine months ended 30 September 2026 of China National Accord
Medicines Corporation Ltd. (“Sinopharm Accord”), a subsidiary of the Company, whose A
shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares:
000028; stock code for B shares: 200028).

The board of directors of the Company would like to draw the attention of its shareholders and
the public investors to the following principal unaudited financial data and indicators of
Sinopharm Accord for the nine months ended 30 September 2026 as set out in the
Announcement.




* The Company is registered as a non-Hong Kong company under the Hong Kong Companies
Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.

1
PRINCIPAL UNAUDITED FINANCIAL DATA AND INDICATORS OF SINOPHARM
ACCORD
Unit: Ten Thousand Yuan
Currency: RMB

January- January-
September September Increase/Decrease
2026 2025
Total Revenue 5,506,609.03 5,512,449.07 -0.11%
Operating profit 132,718.82 133,347.76 -0.47%
Total profit 131,698.99 131,765.48 -0.05%
Net profit attributable to 95,249.00 95,711.85 -0.48%
shareholders of the listed
company
Net profit attributable to 94,477.64 92,301.90 2.36%
shareholders of the listed
company after deducting non-
recurring gains and losses
Basic earnings per share 1.56 1.56 0.00%
(Yuan)
Weighted average return on 5.03% 5.29% Decreased by 0.26
net assets percentage points
July-September July-September Increase/Decrease
2026 2025
Total Revenue 1,879,973.42 1,832,789.23 2.57%
Operating profit 49,275.79 40,698.11 21.08%
Total profit 48,960.50 39,954.15 22.54%
Net profit attributable to 34,628.65 29,121.12 18.91%
shareholders of the listed
company
Net profit attributable to 34,590.22 28,015.75 23.47%
shareholders of the listed
company after deducting non-
recurring gains and losses
Basic earnings per share 0.57 0.48 18.75%
(Yuan)
Weighted average return on net 1.82% 1.59% Increased by 0.23
assets percentage points


2
At the end of the At the beginning of Increase/Decrease
reporting period the reporting
period
Total assets 4,890,375.64 4,909,627.10 -0.39%
Equity attributable to 1,921,961.11 1,860,996.33 3.28%
shareholders of listed company
Share capital (in 0’000 shares) 61,222.16 55,656.51 10.00%
Net assets per share 31.39 30.40 3.26%
attributable to shareholders of
listed company (Yuan)

Notes:

1. The above data are prepared based on the consolidated financial statements of Sinopharm
Accord.

2. At the 2025 annual general meeting of Sinopharm Accord held on 21 May 2026, the “2025
Profit Distribution Proposal of Sinopharm Accord” was approved, pursuant to which a cash
dividend of RMB6.16 per 10 shares (before tax) would be distributed and 1 bonus share per 10
shares would be issued to all shareholders based on a total share capital of 556,565,077 shares
as at the end of 2025, resulting in an issuance of 55,656,507 bonus shares and an increase in
total share capital of Sinopharm Accord to 612,221,584 shares. The equity distribution was
completed for A shares on 24 June 2026 and for B shares on 26 June 2026. In accordance with
the relevant requirements of the “Rules on Information Disclosure and Preparation by
Companies Offering Securities to the Public No. 9 — Calculation and Disclosure of Return on
Net Assets and Earnings Per Share”, Sinopharm Accord has recalculated the earnings per share
for the comparative period based on the total share capital after the bonus share issuance, and
has also recalculated the net assets per share attributable to shareholders of the listed company.
The basic earnings per share for the same period of last year and the net assets per share
attributable to shareholders of the listed company at the end of last year were adjusted from
RMB1.72 and RMB33.44 to RMB1.56 and RMB30.40, respectively.

3. In accordance with the relevant requirements of the “Rules on Information Disclosure and
Preparation by Companies Offering Securities to the Public No. 9 — Calculation and
Disclosure of Return on Net Assets and Earnings Per Share”, Sinopharm Accord has
recalculated the earnings per share for the comparative period based on the total share capital
after the bonus share issuance. The basic earnings per share for the period from July to
September 2025 was adjusted from RMB0.52 to RMB0.48.

INFORMATION OF THE OPERATION RESULTS AND FINANCIAL SITUATION

For the period from January to September 2026, Sinopharm Accord achieved a revenue of
RMB55.066 billion, representing a year-on-year decrease of 0.11%; operating profit of
RMB1.327 billion, representing a year-on-year decrease of 0.47%; total profit of RMB1.317
billion, representing a year-on-year decrease of 0.05%; and net profit attributable to
3
shareholders of the listed company of RMB0.952 billion, representing a year-on-year decrease
of 0.48%. The weighted average return on net assets decreased by 0.26 percentage points year-
on-year. In the third quarter of 2026, Sinopharm Accord achieved a revenue of RMB18.800
billion, representing a year-on-year increase of 2.57%; and net profit attributable to
shareholders of the listed company of RMB0.346 billion, representing a year-on-year increase
of 18.91%. The performance of each segment is as follows:

For the period from January to September 2026, the distribution segment achieved a revenue of
RMB40.565 billion, representing a year-on-year decrease of 0.07%; and net profit of
RMB0.754 billion, representing a year-on-year increase of 4.28%. Despite the continued
deepening of industry policies, Sinopharm Accord remained committed to strengthening its
core business, actively expanding its market presence and adjusting its business structure. The
decline in revenue continued to narrow, while profit growth regained momentum,
demonstrating strong operational resilience. The retail segment (namely “Sinopharm Holding
Guoda Drugstore Co., Ltd.”, hereinafter referred to as “Guoda Drugstore”) achieved a revenue
of RMB15.234 billion, representing a year-on-year increase of 0.05%; and net profit of RMB27
million, representing a year-on-year increase of 105.08%. Guoda Drugstore’s sales revenue
gradually stabilized. Through continuous optimization of its product mix, strategic adjustment
of its store network layout, further strengthening of expense control and enhancement of
operational quality, Guoda Drugstore achieved year-on-year growth in net profit during the
reporting period.

In 2026, the pharmaceutical industry continued to experience the deepening impact of
centralized procurement and other policy measures, with industry competition shifting from
scale expansion to competition in quality and efficiency. Sinopharm Accord will maintain its
strategic focus, proactively adapt to changes in the industry landscape, and continue to enhance
supply chain efficiency through lean operations. By actively expanding incremental markets
and optimizing its product mix to cultivate new growth drivers, Sinopharm Accord will
continue to break through development bottlenecks and steadily improve its operational quality
and profitability.

Shareholders and public investors should note that the principal unaudited financial data
and indicators of Sinopharm Accord during the reporting period contained in this
announcement are only preliminary accounting data, which have not been audited by an
accounting firm, and the final data to be disclosed in the third quarter report of
Sinopharm Accord may differ.



By order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman
Shanghai, the PRC
20 October 2026



4
As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr.
Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr.
Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the
independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr.
Shi Shenghao and Mr. Chen Weiru.




5